drugset
drugset / Trial / NCT00532623

Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer

NCT00532623 ↗

Phase 2 Completed 82 enrolled National Cancer Center, Korea
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the overall response rate of gemcitabine and vinorelbine combination (GV) and gemcitabine followed by vinorelbine (G⇒V) when used as palliative therapy in patients with stage IV and recurrent breast cancer.

Timeline

Start
2004-05
Primary completion
2006-09
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous
Comparator Gemcitabine Small molecule 1200 mg/m2 Intravenous
Comparator Vinorelbine Small molecule 25 mg/m2 Intravenous
Comparator Vinorelbine Small molecule 30 mg/m2 Intravenous

Indications

breast cancer